T9G — Vidac Pharma Holding Cashflow Statement
0.000.00%
Last trade - 00:00Annual cashflow statement for Vidac Pharma Holding, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2021 December 31st | C2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 5 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -0.407 | -0.643 | -1.27 | -1.39 | -1.89 |
| Depreciation | |||||
| Non-Cash Items | 0 | 0.249 | 0.376 | 0.724 | 0.032 |
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.016 | -0.075 | 0.216 | -0.08 | 0.124 |
| Change in Accounts Receivable | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -0.391 | -0.468 | -0.682 | -0.742 | -1.73 |
| Capital Expenditures | 0 | — | — | — | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0 | 0.008 | 0 | 0 | 0 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 0 | 0.008 | 0 | 0 | 0 |
| Financing Cash Flow Items | 0.028 | — | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.282 | 0.401 | 0.715 | 1.15 | 1.52 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.123 | -0.089 | 0.026 | 0.38 | -0.186 |